Agreements reached under this partnership
Capital and Business Alliance- 1
Promotion of joint sales activities, product development and market adoption initiatives in businesses targeting local governments and medical institutions
- 2
Integration of PHR platforms, applications and other services held or provided by the Company and TISI, and joint development of functionality
- 3
Promotion of joint use of data relating to the services in the preceding item
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
This indicates whether the companies will do more than work together, such as holding each other’s shares or seconding personnel (capital and business alliance).
The impact of this matter on consolidated results for the fiscal year ending December 2026 is expected to be immaterial, but the Company believes it will contribute to enhancing corporate value over the medium to long term.
| Item | Details |
|---|---|
| Name of alliance partner | 株式会社TISI |
| Alliance partner's business activities | Outsourcing services and cloud services related to investments in information technology, software development, and the provision of solutions |
| Alliance partner's location | Shinjuku-ku, Tokyo |
| Alliance partner's capital | ¥10,001 million (as of 30 June 2026) |
| Alliance partner's net sales | ¥596,479 million (fiscal year ended March 2026) |
| Alliance partner's operating income | ¥76,229 million (fiscal year ended March 2026) |
| Type of alliance | Capital and Business Alliance |
| Details of the alliance | Promotion of joint sales activities, product development and market adoption initiatives in businesses targeting local governments and medical institutions, Integration of PHR platforms, applications and other services held or provided by the Company and TISI, and joint development of functionality, Promotion of joint use of data relating to the services in the preceding item |
| Number of shares acquired | 1,103 shares, representing 34.01% of the total number of shares issued |
| Shareholding ratio | Not disclosed → 34.01％ |
| Date of board resolution | 20 October 2026 |
| Contract Date | 23 October 2026 (scheduled) |
| Impact on Business Performance | The impact of this matter on consolidated results for the fiscal year ending December 2026 is expected to be immaterial, but the Company believes it will contribute to enhancing corporate value over the medium to long term. |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To advance collaboration among regional medical institutions and the development of networks using PHRs, and to expand the business into the fields of lifestyle-related diseases, cancer and other diseases. In addition, the three companies will jointly plan, develop, market and roll out the services, while mutually leveraging their intellectual property, technology, human resources, sales infrastructure and other resources to improve the functionality of the services concerned and expand the business.